Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival
Annals of Hematology · 2024-03 · 103 (3) · 749-758
DOI: 10.1007/s00277-024-05621-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 20.01.2024. Verfasst von Sohini Chattopadhyay und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Anemia, Aplastic, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
We studied the incidence of relapse, transformation to myelodysplastic syndrome/acute myeloid leukemia, and survival in patients with aplastic anemia (AA) surviving more than 1 year after ATG/ALG-based immunosuppressive therapy (IST) between 1985 and 2020. Four-hundred seventy patients (413 adults and 57 children) were studied, and data were compared with 223 patients who underwent matched sibling donor transplant (MSD HSCT). Median follow-up is 50 months (12-359). Relapse occurred in 21.9% at a median time of 33.5 months (5-228) post IST. Twenty-six (5.5%) patients progressed to PNH, while 20 (4.3%) evolved to MDS/AML. Ten-year estimated overall survival (OS) is 80.9 ± 3% and was significantly better in patients without an event (85.1 ± 4%) compared to relapse (74.6% ± 6.2%) or clonal evolution (12.8% ± 11.8%) (p = 0.024). While the severity of AA (p = 0.011) and type of ATG (p = 0.028) used predicted relapse, only age at IST administration influenced clonal evolution (p = 0.018). Among HSCT recipients, relapse rates were 4.9% with no clonal evolution, and the 10-year OS was 94.5 ± 2%. In patients who survived 1 year following IST, outcomes were good except with clonal evolution to MDS/AML. These outcomes, however, were still inferior compared to matched sibling donor HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Christian Medical College, Vellore, India.
- Department of Haematology, Christian Medical College, Vellore, India. biju@cmcvellore.ac.in.
Zitieren
APA
Chattopadhyay, S., Lionel, S., Selvarajan, S., Devasia, A. J., Korula, A., Kulkarni, U., Aboobacker, F. N., Lakshmi, K. M., Srivastava, A., Mathews, V., Abraham, A., & George, B. (2024). Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival. Annals of Hematology, 103(3), 749-758. https://doi.org/10.1007/s00277-024-05621-2
Vancouver
Chattopadhyay S, Lionel S, Selvarajan S, Devasia AJ, Korula A, Kulkarni U, et al. Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival. Annals of Hematology. 2024;103(3):749-758. doi:10.1007/s00277-024-05621-2
BibTeX
@article{Chattopadhyay2024,
author = {Chattopadhyay, Sohini and Lionel, Sharon and Selvarajan, Sushil and Devasia, Anup J and Korula, Anu and Kulkarni, Uday and Aboobacker, Fouzia N and Lakshmi, Kavitha M and Srivastava, Alok and Mathews, Vikram and Abraham, Aby and George, Biju},
title = {Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {3},
pages = {749--758},
doi = {10.1007/s00277-024-05621-2}
}
EUVIMED